Unity Biotechnology Inc. has raised $116m in Series B venture capital to go after a different set of problems associated with aging than the company’s top executives tackled with their prior company Kythera Biopharmaceuticals Inc.
Kythera, which new Unity CEO Keith Leonard sold to Allergan PLC last year for $2.1bn, developed Kybella (deoxycholic acid) to reduce the appearance of a double chin. Unity was...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?